Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation
✍ Scribed by Dr. Kathy S. Albain; Michelle M. Le Beau; Rudolf Ullirsch; Harold Schumacher
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 558 KB
- Volume
- 2
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
✦ Synopsis
The present case, together with other reports reviewed herein, defines a new subtype of therapy-related acute myeloid leukemia (t-AML). This variant of t-AML is characterized by a short interval from initial drug therapy to bone marrow dysfunction and monocytic morphology without trilineage dysplasia Unlike classic t-AML, which frequently has abnormalities of chromosomes 5 and/or 7, this new subtype is characterized by rearrangements involving band q23 of chromosome I I, most commonly a 9;l I translocation. The majority of patients with this subtype of t-AML had prior cytotoxic therapy with topoisomerase 11-reactive drugs including anthracyclines, epipodophyllotoxins, or actinomycin D, combined with either an alkylating agent or cisplatin. This association of prior therapy which includes topoisomerase Il-reactive agents and a rapidly appearing t-AML involving the monocytic line and chromosome I I requires additional study.